FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241558184> ?p ?o ?g. }

• W4241558184 abstract "Background Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction to colonisation of the lungs with the fungus Aspergillus fumigatus and affects around 10% of people with cystic fibrosis. ABPA is associated with an accelerated decline in lung function. High doses of corticosteroids are the main treatment for ABPA; although the long‐term benefits are not clear, their many side effects are well‐documented. A group of compounds, the azoles, have activity against Aspergillus fumigatus and have been proposed as an alternative treatment for ABPA. Of this group, itraconazole is the most active. A separate antifungal compound, amphotericin B, has been employed in aerosolised form to treat invasive infection with Aspergillus fumigatus, and may have potential for the treatment of ABPA. Antifungal therapy for ABPA in cystic fibrosis needs to be evaluated. Objectives The review aimed to test the hypotheses that antifungal interventions for the treatment of ABPA in cystic fibrosis: 1. improve clinical status compared to placebo or standard therapy (no placebo); 2. do not have unacceptable adverse effects. If benefit was demonstrated, we aimed to assess the optimal type, duration and dose of antifungal therapy. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. In addition, pharmaceutical companies were approached. Date of the most recent search of the Group's Trials Register: 09 February 2012. Selection criteria Published or unpublished randomised controlled trials, where antifungal treatments have been compared to either placebo or no treatment, or where different doses of the same treatment have been used in the treatment of ABPA in people with cystic fibrosis. Data collection and analysis Two trials were identified by the searches; neither was judged eligible for inclusion in the review. Main results No completed randomised controlled trials were included. Authors' conclusions At present, there are no randomised controlled trials to evaluate the use of antifungal therapies for the treatment of ABPA in people with cystic fibrosis. Trials with clear outcome measures are needed to properly evaluate this potentially useful treatment for cystic fibrosis." @default.
• W4241558184 created "2022-05-12" @default.
• W4241558184 creator A5024306774 @default.
• W4241558184 creator A5049835765 @default.
• W4241558184 date "2012-06-13" @default.
• W4241558184 modified "2023-10-18" @default.
• W4241558184 title "Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis" @default.
• W4241558184 cites W1946256898 @default.
• W4241558184 cites W1974893215 @default.
• W4241558184 cites W1988195179 @default.
• W4241558184 cites W1997775131 @default.
• W4241558184 cites W1997855218 @default.
• W4241558184 cites W1998979526 @default.
• W4241558184 cites W2005581514 @default.
• W4241558184 cites W2005894108 @default.
• W4241558184 cites W2075425014 @default.
• W4241558184 cites W2077424676 @default.
• W4241558184 cites W2082792877 @default.
• W4241558184 cites W2120902620 @default.
• W4241558184 cites W2122670779 @default.
• W4241558184 cites W2135649656 @default.
• W4241558184 cites W2136496779 @default.
• W4241558184 cites W2150817537 @default.
• W4241558184 cites W2153044469 @default.
• W4241558184 cites W4245632000 @default.
• W4241558184 cites W92943117 @default.
• W4241558184 doi "https://doi.org/10.1002/14651858.cd002204.pub2" @default.
• W4241558184 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22696329" @default.
• W4241558184 hasPublicationYear "2012" @default.
• W4241558184 type Work @default.
• W4241558184 citedByCount "9" @default.
• W4241558184 countsByYear W42415581842014 @default.
• W4241558184 countsByYear W42415581842016 @default.
• W4241558184 countsByYear W42415581842017 @default.
• W4241558184 countsByYear W42415581842019 @default.
• W4241558184 countsByYear W42415581842021 @default.
• W4241558184 countsByYear W42415581842022 @default.
• W4241558184 crossrefType "reference-entry" @default.
• W4241558184 hasAuthorship W4241558184A5024306774 @default.
• W4241558184 hasAuthorship W4241558184A5049835765 @default.
• W4241558184 hasConcept C126322002 @default.
• W4241558184 hasConcept C141105273 @default.
• W4241558184 hasConcept C142724271 @default.
• W4241558184 hasConcept C159654299 @default.
• W4241558184 hasConcept C16005928 @default.
• W4241558184 hasConcept C177713679 @default.
• W4241558184 hasConcept C197934379 @default.
• W4241558184 hasConcept C203014093 @default.
• W4241558184 hasConcept C204787440 @default.
• W4241558184 hasConcept C27081682 @default.
• W4241558184 hasConcept C2776391196 @default.
• W4241558184 hasConcept C2776938444 @default.
• W4241558184 hasConcept C2777071850 @default.
• W4241558184 hasConcept C2778871687 @default.
• W4241558184 hasConcept C2779548794 @default.
• W4241558184 hasConcept C2779629538 @default.
• W4241558184 hasConcept C2779787849 @default.
• W4241558184 hasConcept C2780690907 @default.
• W4241558184 hasConcept C71924100 @default.
• W4241558184 hasConceptScore W4241558184C126322002 @default.
• W4241558184 hasConceptScore W4241558184C141105273 @default.
• W4241558184 hasConceptScore W4241558184C142724271 @default.
• W4241558184 hasConceptScore W4241558184C159654299 @default.
• W4241558184 hasConceptScore W4241558184C16005928 @default.
• W4241558184 hasConceptScore W4241558184C177713679 @default.
• W4241558184 hasConceptScore W4241558184C197934379 @default.
• W4241558184 hasConceptScore W4241558184C203014093 @default.
• W4241558184 hasConceptScore W4241558184C204787440 @default.
• W4241558184 hasConceptScore W4241558184C27081682 @default.
• W4241558184 hasConceptScore W4241558184C2776391196 @default.
• W4241558184 hasConceptScore W4241558184C2776938444 @default.
• W4241558184 hasConceptScore W4241558184C2777071850 @default.
• W4241558184 hasConceptScore W4241558184C2778871687 @default.
• W4241558184 hasConceptScore W4241558184C2779548794 @default.
• W4241558184 hasConceptScore W4241558184C2779629538 @default.
• W4241558184 hasConceptScore W4241558184C2779787849 @default.
• W4241558184 hasConceptScore W4241558184C2780690907 @default.
• W4241558184 hasConceptScore W4241558184C71924100 @default.
• W4241558184 hasLocation W42415581841 @default.
• W4241558184 hasLocation W42415581842 @default.
• W4241558184 hasOpenAccess W4241558184 @default.
• W4241558184 hasPrimaryLocation W42415581841 @default.
• W4241558184 hasRelatedWork W2067840748 @default.
• W4241558184 hasRelatedWork W2074149293 @default.
• W4241558184 hasRelatedWork W2119800013 @default.
• W4241558184 hasRelatedWork W2126521105 @default.
• W4241558184 hasRelatedWork W2143036279 @default.
• W4241558184 hasRelatedWork W2156755613 @default.
• W4241558184 hasRelatedWork W2416781282 @default.
• W4241558184 hasRelatedWork W2484496567 @default.
• W4241558184 hasRelatedWork W2509805462 @default.
• W4241558184 hasRelatedWork W3021009728 @default.
• W4241558184 isParatext "false" @default.
• W4241558184 isRetracted "false" @default.
• W4241558184 workType "reference-entry" @default.